From Diligence To Execution — Tim Wright's Approach To Leading MiMedx
Source: Life Science Leader
By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
“The Bad News Keeps Coming For MiMedx And Its New Auditor EY,” read the July 3, 2018, MarketWatch headline.
The publicly traded biopharma faced an accounting scandal involving three former executives (i.e., CEO, COO, and CFO), and consequently, would have to restate more than five years of financials. And more trouble would soon follow. It makes you wonder what type of person would want to take on leading a company that was facing such significant reputational challenges. How about 36-year biopharma veteran Tim Wright?
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader